阿斯利康与百时美施贵宝洽谈合并，股价异动引分析师困惑

AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.